Skip to main content
Skip to search
Skip to main menu
Skip to page specific menu
Skip to footer area
Site Menu
Buscar
Close Search
Search the Schiffer Lab site
Buscar
A-Z
|
Search All UMass Chan Sites
Buscar
Close Search
Search the Schiffer Lab site
Buscar
A-Z
|
Search All UMass Chan Sites
Schiffer Lab
Biochemistry and Molecular Biotechnology
Research
Research
Overview: Drug Resistance
Molecular Basis for Resistance
Substrate Envelope
Inhibitor Design
Integrated Strategies to Elucidate Molecular Recognition
Introducing Sequence Diversity: APOBEC3s
Scientific Leadership
Scientific Leadership
About Celia Schiffer
Institute for Drug Resistance
Structure Based Drug Design Core
Cryo EM Core Facility
Publications
Publications
Dissertations
Journal Publications
People
People
Current Members
Alumni
In the News
Additional Resources
Page Menu
x
Publications
Dissertations
Journal Publications
Publications
Dissertations
Journal Publications
Publications
Total:
50
results
Contributions of Hyperactive Mutations in Mpro from SARS-CoV-2 to Drug Resistance
marzo 12, 2024
Author(s):
Julia M Flynn,Sarah N Zvornicanin,Tenzin Tsepal,Ala M Shaqra,Nese Kurt Yilmaz,Weiping Jia,Stephanie Moquin,Dustin Dovala,Celia A Schiffer,Daniel N A Bolon
Source:
ACS infectious diseases
The appearance and spread of mutations that cause drug resistance in rapidly evolving diseases, including infections by the SARS-CoV-2 virus, are major concerns for human health. Many drugs target enz...
Direct delivery of stabilized Cas-embedded base editors achieves efficient and accurate editing of clinically relevant targets
febrero 19, 2024
Author(s):
Jeong Min Lee,Jing Zeng,Pengpeng Liu,My Anh Nguyen,Diego Suchenski Loustaunau,Daniel E Bauer,Nese Kurt Yilmaz,Scot A Wolfe,Celia A Schiffer
Source:
bioRxiv : the preprint server for biology
Over the last 5 years, cytosine base editors (CBEs) have emerged as a promising therapeutic tool for specific editing of single nucleotide variants and disrupting specific genes associated with diseas...
Project Confirm: Accelerated Drug Approvals for CML-Response
enero 05, 2024
Author(s):
Kendra L Sweet,Jorge E Cortes,Jane F Apperley,Mel Mann,Michael J Mauro,Vivian G Oehler,Cristina Ruiz,Charles A Schiffer,Lori A Ehrlich,Gulsum E Pamuk,Joseph Wynne,Gautam U Mehta,Olanrewaju O Okusanya,...
Source:
Clinical cancer research : an official journal of the American Association for Cancer Research
No abstract
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
noviembre 09, 2023
Author(s):
Melissa L Boby,Daren Fearon,Matteo Ferla,Mihajlo Filep,Lizbé Koekemoer,Matthew C Robinson,COVID Moonshot Consortium‡,John D Chodera,Alpha A Lee,Nir London,Annette von Delft,Frank von Delft,Hagit Achdo...
Source:
Science (New York, N.Y.)
We report the results of the COVID Moonshot, a fully open-science, crowdsourced, and structure-enabled drug discovery campaign targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2...
Addressing the dNTP bottleneck restricting prime editing activity
octubre 31, 2023
Author(s):
Karthikeyan Ponnienselvan,Pengpeng Liu,Thomas Nyalile,Sarah Oikemus,Anya T Joynt,Karen Kelly,Dongsheng Guo,Zexiang Chen,Jeong Min Lee,Celia A Schiffer,Charles P Emerson,Nathan D Lawson,Jonathan K Watt...
Source:
bioRxiv : the preprint server for biology
Prime editing efficiency is modest in cells that are quiescent or slowly proliferating where intracellular dNTP levels are tightly regulated. MMLV-reverse transcriptase - the prime editor polymerase s...
Glasdigib fails to slay the hedgehog in pivotal AML trials
octubre 10, 2023
Author(s):
Charles A Schiffer
Source:
Leukemia
No abstract
FruitFire: a luciferase based on a fruit fly metabolic enzyme
julio 10, 2023
Author(s):
Spencer T Adams,Jacqueto Zephyr,Markus F Bohn,Celia A Schiffer,Stephen C Miller
Source:
bioRxiv : the preprint server for biology
Firefly luciferase is homologous to fatty acyl-CoA synthetases from insects that are not bioluminescent. Here, we determined the crystal structure of the fruit fly fatty acyl-CoA synthetase CG6178 to ...
Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease
junio 30, 2023
Author(s):
Julia M Flynn,Qiu Yu J Huang,Sarah N Zvornicanin,Gila Schneider-Nachum,Ala M Shaqra,Nese Kurt Yilmaz,Stephanie A Moquin,Dustin Dovala,Celia A Schiffer,Daniel N A Bolon
Source:
ACS infectious diseases
Drugs that target the main protease (M^(pro)) of SARS-CoV-2 are effective therapeutics that have entered clinical use. Wide-scale use of these drugs will apply selection pressure for the evolution of ...
HIV-1 protease inhibitors with a P1 phosphonate modification maintain potency against drug-resistant variants by increased interactions with flap residues
mayo 27, 2023
Author(s):
Gordon J Lockbaum,Linah N Rusere,Mina Henes,Klajdi Kosovrasti,Desaboini Nageswara Rao,Ean Spielvogel,Sook-Kyung Lee,Ellen A Nalivaika,Ronald Swanstrom,Nese Kurt Yilmaz,Celia A Schiffer,Akbar Ali
Source:
European journal of medicinal chemistry
Protease inhibitors are the most potent antivirals against HIV-1, but they still lose efficacy against resistant variants. Improving the resistance profile is key to developing more robust inhibitors,...
New patterns of genetic instability in chronic myeloid leukemia: interesting, but not ready for clinical use
abril 20, 2023
Author(s):
Charles A Schiffer
Source:
Haematologica
No abstract
Crystal Structures of Inhibitor-Bound Main Protease from Delta- and Gamma-Coronaviruses
marzo 30, 2023
Author(s):
Sarah N Zvornicanin,Ala M Shaqra,Qiuyu J Huang,Elizabeth Ornelas,Mallika Moghe,Mark Knapp,Stephanie Moquin,Dustin Dovala,Celia A Schiffer,Nese Kurt Yilmaz
Source:
Viruses
With the spread of SARS-CoV-2 throughout the globe causing the COVID-19 pandemic, the threat of zoonotic transmissions of coronaviruses (CoV) has become even more evident. As human infections have bee...
Selection of HIV-1 for resistance to fifth-generation protease inhibitors reveals two independent pathways to high-level resistance
marzo 15, 2023
Author(s):
Ean Spielvogel,Sook-Kyung Lee,Shuntai Zhou,Gordon J Lockbaum,Mina Henes,Amy Sondgeroth,Klajdi Kosovrasti,Ellen A Nalivaika,Akbar Ali,Nese Kurt Yilmaz,Celia A Schiffer,Ronald Swanstrom
Source:
eLife
Darunavir (DRV) is exceptional among potent HIV-1 protease inhibitors (PIs) in high drug concentrations that are achieved in vivo. Little is known about the de novo resistance pathway for DRV. We sele...
Non-canonical pattern recognition of a pathogen-derived metabolite by a nuclear hormone receptor identifies virulent bacteria in C. elegans
febrero 22, 2023
Author(s):
Nicholas D Peterson,Samantha Y Tse,Qiuyu Judy Huang,Khursheed A Wani,Celia A Schiffer,Read Pukkila-Worley
Source:
Immunity
Distinguishing infectious pathogens from harmless microorganisms is essential for animal health. The mechanisms used to identify infectious microbes are not fully understood, particularly in metazoan ...
Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia
diciembre 22, 2022
Author(s):
Kendra L Sweet,Jorge E Cortes,Jane F Apperley,Mel Mann,Michael J Mauro,Vivian G Oehler,Cristina Ruiz,Charles A Schiffer,Lori A Ehrlich,Gulsum E Pamuk,Joseph Wynne,Gautam U Mehta,R Angelo de Claro,Marc...
Source:
Clinical cancer research : an official journal of the American Association for Cancer Research
The FDA has an accelerated approval program for drugs that have been identified as promising treatments for serious conditions when the available data suggest that the benefits outweigh the foreseeabl...
Allosteric quinoxaline-based inhibitors of the flavivirus NS2B/NS3 protease
noviembre 29, 2022
Author(s):
Jacqueto Zephyr,Desaboini Nageswara Rao,Colby Johnson,Ala M Shaqra,Ellen A Nalivaika,Aria Jordan,Nese Kurt Yilmaz,Akbar Ali,Celia A Schiffer
Source:
Bioorganic chemistry
Viruses from the Flavivirus genus infect millions of people worldwide and cause severe diseases, including recent epidemics of dengue virus (DENV), and Zika virus (ZIKV). There is currently no antivir...
Structure of the catalytically active APOBEC3G bound to a DNA oligonucleotide inhibitor reveals tetrahedral geometry of the transition state
noviembre 19, 2022
Author(s):
Atanu Maiti,Adam K Hedger,Wazo Myint,Vanivilasini Balachandran,Jonathan K Watts,Celia A Schiffer,Hiroshi Matsuo
Source:
Nature communications
APOBEC3 proteins (A3s) are enzymes that catalyze the deamination of cytidine to uridine in single-stranded DNA (ssDNA) substrates, thus playing a key role in innate antiviral immunity. However, the AP...
Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2
noviembre 10, 2022
Author(s):
Santanu Mondal,Yongzhi Chen,Gordon J Lockbaum,Sudeshna Sen,Sauradip Chaudhuri,Archie C Reyes,Jeong Min Lee,Arshia N Kaur,Nadia Sultana,Michael D Cameron,Scott A Shaffer,Celia A Schiffer,Katherine A Fi...
Source:
Journal of the American Chemical Society
Given the current impact of SARS-CoV2 and COVID-19 on human health and the global economy, the development of direct acting antivirals is of paramount importance. Main protease (M^(Pro)), a cysteine p...
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants
septiembre 29, 2022
Author(s):
Qi Li,Fiachra Humphries,Roxie C Girardin,Aaron Wallace,Monir Ejemel,Alla Amcheslavsky,Conor T McMahon,Zachary A Schiller,Zepei Ma,John Cruz,Alan P Dupuis,Anne F Payne,Arooma Maryam,Nese Kurt Yilmaz,Ka...
Source:
Frontiers in immunology
Anti-COVID antibody therapeutics have been developed but not widely used due to their high cost and escape of neutralization from the emerging variants. Here, we describe the development of VHH-IgA1.1...
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
junio 29, 2022
Author(s):
Daniel A Arber,Attilio Orazi,Robert P Hasserjian,Michael J Borowitz,Katherine R Calvo,Hans-Michael Kvasnicka,Sa A Wang,Adam Bagg,Tiziano Barbui,Susan Branford,Carlos E Bueso-Ramos,Jorge E Cortes,Paola...
Source:
Blood
The classification of myeloid neoplasms and acute leukemias was last updated in 2016 within a collaboration between the World Health Organization (WHO), the Society for Hematopathology, and the Europe...
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
junio 21, 2022
Author(s):
Ala M Shaqra,Sarah N Zvornicanin,Qiu Yu J Huang,Gordon J Lockbaum,Mark Knapp,Laura Tandeske,David T Bakan,Julia Flynn,Daniel N A Bolon,Stephanie Moquin,Dustin Dovala,Nese Kurt Yilmaz,Celia A Schiffer
Source:
Nature communications
Coronaviruses can evolve and spread rapidly to cause severe disease morbidity and mortality, as exemplified by SARS-CoV-2 variants of the COVID-19 pandemic. Although currently available vaccines remai...
Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
junio 20, 2022
Author(s):
Julia M Flynn,Neha Samant,Gily Schneider-Nachum,David T Barkan,Nese Kurt Yilmaz,Celia A Schiffer,Stephanie A Moquin,Dustin Dovala,Daniel N A Bolon
Source:
eLife
With the continual evolution of new strains of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that are more virulent, transmissible, and able to evade current vaccines, there is an urgen...
Racial disparities in time to hematopoietic cell transplant among patients with hematologic malignancies at a large urban academic center
mayo 17, 2022
Author(s):
Harsh Shah,Seongho Kim,Scott Klimecki,Karl Charlson,Joseph Uberti,Charles A Schiffer,Mark A Fiala,Erlene Seymour
Source:
Bone marrow transplantation
No abstract
HIV-1 VIF and human APOBEC3G interaction directly observed through molecular specific labeling using a new dual promotor vector
mayo 13, 2022
Author(s):
Wazo Myint,Celia A Schiffer,Hiroshi Matsuo
Source:
Journal of magnetic resonance (San Diego, Calif. : 1997)
Over the last few decades, protein NMR isotope labeling methods using E. coli based expression have revolutionized the information accessible from biomolecular NMR experiments. Selective labeling of a...
An evaluation of ponatinib as a therapy in adult patients with resistant/intolerant chronic-phase chronic myeloid leukemia
mayo 11, 2022
Author(s):
Jay Yang,Malini Surapaneni,Charles A Schiffer
Source:
Expert review of hematology
INTRODUCTION: Chronic myeloid leukemia is now a highly treatable leukemia due to the availability of multiple tyrosine kinase inhibitors (TKIs) inhibiting the BCR-ABL1 oncogene. Some patients with CML...
Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia
mayo 05, 2022
Author(s):
Kathryn E Flynn,Ehab Atallah,Li Lin,Neil P Shah,Richard T Silver,Richard A Larson,Javier Panilla-Ibarz,James E Thompson,Vivian G Oehler,Jerald P Radich,Vamsi Kota,Michael J Mauro,Charles A Schiffer,Jo...
Source:
Haematologica
For patients with optimally treated chronic myeloid leukemia (CML), discontinuation of tyrosine kinase inhibitor (TKI) therapy can lead to treatment-free remission. In previous trials, TKI discontinua...
Analyses of HIV proteases variants at the threshold of viability reveals relationships between processing efficiency and fitness
marzo 18, 2022
Author(s):
Gily Schneider-Nachum,Julia Flynn,David Mavor,Celia A Schiffer,Daniel N A Bolon
Source:
Virus evolution
Investigating the relationships between protein function and fitness provides keys for understanding biochemical mechanisms that underly evolution. Mutations with partial fitness defects can delineate...
Quantitative structural analysis of influenza virus by cryo-electron tomography and convolutional neural networks
marzo 15, 2022
Author(s):
Qiuyu J Huang,Kangkang Song,Chen Xu,Daniel N A Bolon,Jennifer P Wang,Robert W Finberg,Celia A Schiffer,Mohan Somasundaran
Source:
Structure (London, England : 1993)
Influenza viruses pose severe public health threats globally. Influenza viruses are extensively pleomorphic, in shape, size, and organization of viral proteins. Analysis of influenza morphology and ul...
Call for Papers: Drug Resistance in Infectious Diseases and Beyond
marzo 09, 2022
Author(s):
Celia A Schiffer,Daria J Hazuda
Source:
ACS infectious diseases
No abstract
Deciphering the Molecular Mechanism of HCV Protease Inhibitor Fluorination as a General Approach to Avoid Drug Resistance
febrero 20, 2022
Author(s):
Jacqueto Zephyr,Desaboini Nageswara Rao,Sang V Vo,Mina Henes,Klajdi Kosovrasti,Ashley N Matthew,Adam K Hedger,Jennifer Timm,Elise T Chan,Akbar Ali,Nese Kurt Yilmaz,Celia A Schiffer
Source:
Journal of molecular biology
Third generation Hepatitis C virus (HCV) NS3/4A protease inhibitors (PIs), glecaprevir and voxilaprevir, are highly effective across genotypes and against many resistant variants. Unlike earlier PIs, ...
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach
febrero 18, 2022
Author(s):
Daniel A Arber,Robert P Hasserjian,Attilio Orazi,Vikram Mathews,Andrew W Roberts,Charles A Schiffer,Anne Stidsholt Roug,Mario Cazzola,Hartmut Döhner,Ayalew Tefferi
Source:
American journal of hematology
No abstract
Commentary on the prescient observations made by Emil J Freireich in Effectiveness of platelet transfusion in leukemia and aplastic anemia (Transfusion 1966; 6: 50-54)
febrero 11, 2022
Author(s):
Charles A Schiffer
Source:
Transfusion
No abstract
Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y
enero 19, 2022
Author(s):
Li Jiang,Neha Samant,Ping Liu,Mohan Somasundaran,Jeffrey D Jensen,Wayne A Marasco,Timothy F Kowalik,Celia A Schiffer,Robert W Finberg,Jennifer P Wang,Daniel N A Bolon
Source:
Journal of virology
Many oseltamivir resistance mutations exhibit fitness defects in the absence of drug pressure that hinders their propagation in hosts. Secondary permissive mutations can rescue fitness defects and fac...
Viral proteases: Structure, mechanism and inhibition
diciembre 04, 2021
Author(s):
Jacqueto Zephyr,Nese Kurt Yilmaz,Celia A Schiffer
Source:
The Enzymes
Viral proteases are diverse in structure, oligomeric state, catalytic mechanism, and substrate specificity. This chapter focuses on proteases from viruses that are relevant to human health: human immu...
Asciminib for CML: same target, new arrow
noviembre 25, 2021
Author(s):
Charles A Schiffer
Source:
Blood
No abstract
Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode
septiembre 10, 2021
Author(s):
Gordon J Lockbaum,Mina Henes,Jeong Min Lee,Jennifer Timm,Ellen A Nalivaika,Paul R Thompson,Nese Kurt Yilmaz,Celia A Schiffer
Source:
Biochemistry
Rupintrivir targets the 3C cysteine proteases of the picornaviridae family, which includes rhinoviruses and enteroviruses that cause a range of human diseases. Despite being a pan-3C protease inhibito...
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors
septiembre 07, 2021
Author(s):
Kelly L Schoenbeck,Ehab Atallah,Li Lin,Kevin P Weinfurt,Jorge Cortes,Michael W N Deininger,Vamsi Kota,Richard A Larson,Michael J Mauro,Vivian G Oehler,Javier Pinilla-Ibarz,Jerald P Radich,Charles A Sc...
Source:
Journal of the National Cancer Institute
Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Pa...
Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial
agosto 18, 2021
Author(s):
Jorge Cortes,Jane Apperley,Elza Lomaia,Beatriz Moiraghi,Maria Undurraga Sutton,Carolina Pavlovsky,Charles Chuah,Tomasz Sacha,Jeffrey H Lipton,Charles A Schiffer,James McCloskey,Andreas Hochhaus,Philip...
Source:
Blood
In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to multiple prior tyrosine kinase inh...
How to Effectively Decrease Patient Co-Payments of High-Cost Drugs Through Innovation: Lessons From the Karmanos Specialty Pharmacy
agosto 18, 2021
Author(s):
Erlene K Seymour,Lucius Daniel,Eva Pointer,Jordan Julian,Stephen T Smith,Charles A Schiffer
Source:
JCO oncology practice
CONCLUSION: Twenty-seven percent of patients (22% of prescriptions fills) in 2019 required additional FA for high-cost drugs. KSP substantially reduced patient cost by implementing an efficient proces...
Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants
agosto 18, 2021
Author(s):
Desaboini Nageswara Rao,Jacqueto Zephyr,Mina Henes,Elise T Chan,Ashley N Matthew,Adam K Hedger,Hasahn L Conway,Mohsan Saeed,Alicia Newton,Christos J Petropoulos,Wei Huang,Nese Kurt Yilmaz,Celia A Schi...
Source:
Journal of medicinal chemistry
The three pan-genotypic HCV NS3/4A protease inhibitors (PIs) currently in clinical use-grazoprevir, glecaprevir, and voxilaprevir-are quinoxaline-based P2-P4 macrocycles and thus exhibit similar resis...
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
julio 31, 2021
Author(s):
Frauke Muecksch,Yiska Weisblum,Christopher O Barnes,Fabian Schmidt,Dennis Schaefer-Babajew,Zijun Wang,Julio C C Lorenzi,Andrew I Flyak,Andrew T DeLaitsch,Kathryn E Huey-Tubman,Shurong Hou,Celia A Schi...
Source:
Immunity
Antibodies elicited by infection accumulate somatic mutations in germinal centers that can increase affinity for cognate antigens. We analyzed 6 independent groups of clonally related severe acute res...
Granulocyte transfusions in haematopoietic cell transplants and leukaemia: the phoenix or beating a dead horse?
julio 04, 2021
Author(s):
Robert Peter Gale,Charles A Schiffer,Hillard M Lazarus
Source:
Bone marrow transplantation
No abstract
Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s
junio 25, 2021
Author(s):
Shurong Hou,Jeong Min Lee,Wazo Myint,Hiroshi Matsuo,Nese Kurt Yilmaz,Celia A Schiffer
Source:
The Journal of biological chemistry
The human cytidine deaminase family of APOBEC3s (A3s) plays critical roles in both innate immunity and the development of cancers. A3s comprise seven functionally overlapping but distinct members that...
Deciphering Antifungal Drug Resistance in Pneumocystis jirovecii DHFR with Molecular Dynamics and Machine Learning
junio 17, 2021
Author(s):
Florian Leidner,Nese Kurt Yilmaz,Celia A Schiffer
Source:
Journal of chemical information and modeling
Drug resistance impacts the effectiveness of many new therapeutics. Mutations in the therapeutic target confer resistance; however, deciphering which mutations, often remote from the enzyme active sit...
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
junio 10, 2021
Author(s):
Matthew D Hall,James M Anderson,Annaliesa Anderson,David Baker,Jay Bradner,Kyle R Brimacombe,Elizabeth A Campbell,Kizzmekia S Corbett,Kara Carter,Sara Cherry,Lillian Chiang,Tomas Cihlar,Emmie de Wit,M...
Source:
The Journal of infectious diseases
The NIH Virtual SARS-CoV-2 Antiviral Summit, held on 6 November 2020, was organized to provide an overview on the status and challenges in developing antiviral therapeutics for coronavirus disease 201...
Deciphering Complex Mechanisms of Resistance and Loss of Potency through Coupled Molecular Dynamics and Machine Learning
marzo 30, 2021
Author(s):
Florian Leidner,Nese Kurt Yilmaz,Celia A Schiffer
Source:
Journal of chemical theory and computation
Drug resistance threatens many critical therapeutics through mutations in the drug target. The molecular mechanisms by which combinations of mutations, especially those remote from the active site, al...
Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
marzo 24, 2021
Author(s):
Frauke Muecksch,Yiska Weisblum,Christopher O Barnes,Fabian Schmidt,Dennis Schaefer-Babajew,Julio C C Lorenzi,Andrew I Flyak,Andrew T DeLaitsch,Kathryn E Huey-Tubman,Shurong Hou,Celia A Schiffer,Christ...
Source:
bioRxiv : the preprint server for biology
Antibodies elicited in response to infection undergo somatic mutation in germinal centers that can result in higher affinity for the cognate antigen. To determine the effects of somatic mutation on th...
Introduction: Drug Resistance
marzo 24, 2021
Author(s):
Nese Kurt Yilmaz,Celia A Schiffer
Source:
Chemical reviews
No abstract
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia
marzo 23, 2021
Author(s):
Kerry A Rogers,Leslie A Andritsos,Lai Wei,Eric M McLaughlin,Amy S Ruppert,Mirela Anghelina,James S Blachly,Timothy Call,Dai Chihara,Anees Dauki,Ling Guo,S Percy Ivy,Lacey R James,Daniel Jones,Robert J...
Source:
Blood
Hairy cell leukemia (HCL) is a rare B-cell malignancy, and there is a need for novel treatments for patients who do not benefit from purine analogs. Ibrutinib, an oral agent targeting Bruton tyrosine ...
Inhibiting HTLV-1 Protease: A Viable Antiviral Target
febrero 23, 2021
Author(s):
Gordon J Lockbaum,Mina Henes,Nathaniel Talledge,Linah N Rusere,Klajdi Kosovrasti,Ellen A Nalivaika,Mohan Somasundaran,Akbar Ali,Louis M Mansky,Nese Kurt Yilmaz,Celia A Schiffer
Source:
ACS chemical biology
Human T-cell lymphotropic virus type 1 (HTLV-1) is a retrovirus that can cause severe paralytic neurologic disease and immune disorders as well as cancer. An estimated 20 million people worldwide are ...
NAD(H) phosphates mediate tetramer assembly of human C-terminal binding protein (CtBP)
febrero 01, 2021
Author(s):
Jeffry C Nichols,Celia A Schiffer,William E Royer
Source:
The Journal of biological chemistry
C-terminal binding proteins (CtBPs) are cotranscriptional factors that play key roles in cell fate. We have previously shown that NAD(H) promotes the assembly of similar tetramers from either human Ct...
Back To Top ▲
Close
Research
Research
Overview: Drug Resistance
Molecular Basis for Resistance
Substrate Envelope
Inhibitor Design
Integrated Strategies to Elucidate Molecular Recognition
Introducing Sequence Diversity: APOBEC3s
Scientific Leadership
Scientific Leadership
About Celia Schiffer
Institute for Drug Resistance
Structure Based Drug Design Core
Cryo EM Core Facility
Publications
Publications
Dissertations
Journal Publications
People
People
Current Members
Alumni
In the News
Additional Resources